MyndBlue
Cambridge-based MyndBlue, a digital therapeutic firm, enhances precision in medicine for MDD and PTSD treatment.
Founded
2015Cambridge-based MyndBlue, a digital therapeutic firm, enhances precision in medicine for MDD and PTSD treatment.
Founded in Cambridge, Massachusetts, MyndBlue is a digital therapeutic company dedicated to enhancing precision and personalization in medicine, particularly for Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD). Their core mission is to enable physicians to detect and predict mental health issues in real-time, facilitating earlier interventions and more successful treatments. MyndBlue leverages predictive biomarkers and artificial intelligence to foresee potential relapses, aiming to improve patient outcomes and overall quality of life.
MyndBlue's team includes psychiatrists and clinical psychologists who bring extensive expertise in mental health. The company has attracted notable investors and partners within the healthcare and technology sectors, contributing to its rapid development and implementation of innovative solutions. Key achievements include the successful integration of AI-driven predictive models into clinical practice, significantly reducing relapse rates for MDD and PTSD patients. MyndBlue's impact is marked by its contribution to the field of digital therapeutics, offering a promising approach to managing and treating mental health disorders.
Companies similar to MyndBlue include MyndYou, Oui Therapeutics, Mindstrong and Blue Note Therapeutics.
MyndBlue was founded in 2015.
MyndBlue's most recent funding round was for €1.5M (EUR) in June 2017.
As of Jun 30, 2017, MyndBlue has disclosed funding of €1.5M (EUR). Undisclosed round amounts are excluded.
MyndBlue has 30 employees as of Feb 4, 2024.
